Severe Late-Onset Drug-Induced Immune Thrombocytopenia Following IFN β-1a Treatment: A Case Report of a 52-Year-Old Woman with Relapse-Remitting Multiple Sclerosis
Interferon β-1a (IFNβ1a) is considered safe in relapsing-remitting multiple sclerosis (RRMS). Drug-induced thrombocytopenia (DITP) is a rare but underreported adverse event that is often confused with other causes of thrombocytopenia. We report the case of a 52-year-old woman who developed limb and...
Saved in:
Main Authors: | Christophe Cisarovsky, Marie Théaudin, Pierre-Alexandre Bart, Grégoire Stalder, Lorenzo Alberio |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2022/2767031 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comorbidity in in patients with relapsing-remitting multiple sclerosis
by: O.V. Somilo, et al.
Published: (2024-10-01) -
A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis
by: Naoko Shiba, et al.
Published: (2018-01-01) -
Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
by: S. Migliore, et al.
Published: (2017-01-01) -
Decrease of Mutual Information in Brain Electrical Activity of Patients with Relapsing-Remitting Multiple Sclerosis
by: Bruno Lenne, et al.
Published: (2013-01-01) -
Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022-10-01)